2024
Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes.
Martino M, Galderisi A, Evans-Molina C, Dayan C. Revisiting the Pattern of Loss of β-Cell Function in Preclinical Type 1 Diabetes. Diabetes 2024, 73: 1769-1779. PMID: 39106185, DOI: 10.2337/db24-0163.Peer-Reviewed Original ResearchB cell functionBeta cell lossType 1 diabetesLoss of B-cell functionCell lossOral glucose tolerance testPreclinical type 1 diabetesEarly stage diseaseBeta cell destructionTime of diagnosisDestruction of B cellsGlucose tolerance testMonths prior to clinical diagnosisAntibody positivityStage diseaseDisease activityAutoimmune destructionB cellsDisease accelerationInsulin therapyTolerance testInsulin secretionSubmaximal stimuliCell destructionGlucose controlContinuous glucose monitoring in neonates: challenges and opportunities
Puzone S, Diplomatico M, Galderisi A, Montaldo P. Continuous glucose monitoring in neonates: challenges and opportunities. Journal Of Perinatology 2024, 44: 1382-1383. PMID: 38942928, DOI: 10.1038/s41372-024-02041-y.Peer-Reviewed Original ResearchThe Impact of Antenatal Corticosteroids on the Metabolome of Preterm Newborns: An Untargeted Approach
Valerio E, Meneghelli M, Stocchero M, Galderisi A, Visentin S, Bonadies L, Pirillo P, Poloniato G, Giordano G, Baraldi E. The Impact of Antenatal Corticosteroids on the Metabolome of Preterm Newborns: An Untargeted Approach. International Journal Of Molecular Sciences 2024, 25: 5860. PMID: 38892043, PMCID: PMC11172597, DOI: 10.3390/ijms25115860.Peer-Reviewed Original ResearchAntenatal corticosteroidsPreterm infantsPreterm newbornsInvasive ventilationClinical outcomesMass spectrometry-based untargeted metabolomics analysisImpact of antenatal corticosteroidsTiming of antenatal corticosteroidsMetabolomic analysisNeonatal intensive care unitPostnatal clinical outcomesPadova University HospitalRecommended time windowUntargeted metabolomics analysisElevated levelsImprove respiratory outcomesIntensive care unitUrinary metabolomeLabor onsetAnti-inflammatory propertiesMetabolomic profilesDepartment of womenUniversity HospitalCare unitRespiratory outcomesEndpoints for clinical trials in type 1 diabetes drug development
Galderisi A, Marks B, DiMeglio L, de Beaufort C. Endpoints for clinical trials in type 1 diabetes drug development. The Lancet Diabetes & Endocrinology 2024, 12: 297-299. PMID: 38663944, PMCID: PMC11230104, DOI: 10.1016/s2213-8587(24)00097-4.Peer-Reviewed Original ResearchGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2024, 190: l7-l7. PMID: 38668689, DOI: 10.1093/ejendo/lvae042.Peer-Reviewed Original ResearchImpact of macronutrients intake on glycemic homeostasis of preterm infants: evidence from continuous glucose monitoring
Guiducci S, Res G, Bonadies L, Savio F, Brigadoi S, Priante E, Trevisanuto D, Baraldi E, Galderisi A. Impact of macronutrients intake on glycemic homeostasis of preterm infants: evidence from continuous glucose monitoring. European Journal Of Pediatrics 2024, 183: 3013-3018. PMID: 38637447, PMCID: PMC11192807, DOI: 10.1007/s00431-024-05532-4.Peer-Reviewed Original ResearchPreterm infantsMacronutrient intakeGlucose profilesGestational ageContinuous glucose monitoringNutritional intakeParenteral nutrient intakesGlycemic homeostasisWeeks gestational ageSensor glucoseExposure to hyperglycemiaGlucose monitoringBlood glucose profilesParenteral nutritionHigher lipid intakeMild hypoglycemiaAmino acid intakeSevere hyperglycemiaSevere hypoglycemiaAcid intakeLipid intakeNutrient intakeInfantsPretermHyperglycemiaObesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2024, vol1:608-vol1:616. DOI: 10.1201/9781003437734-70.ChaptersNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityAssociated with precocious pubertyDevelopment of prediabetesCardiometabolic risk factorsPathogenesis of insulin resistanceFatty liver diseasePrecocious pubertyClinical peculiaritiesPediatric obesityLiver diseaseRisk factorsGlobal health challengeMetabolic disordersObesityFatty liverPathological complicationsPotential mechanismsInsulinHealth challengesChildrenComplicationsDyslipidemiaWilliams Textbook of Endocrinology
Chapter 36 : Digitalized Approaches to Diabetes Diagnostics and Therapeutics. Battelino T, Sherr J, Galderisi A, Dovc K. in pressChapters
2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroupGlucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring
Galderisi A, Kariyawasam D, Stoupa A, Quoc A, Pinto G, Viaud M, Brabant S, Beltrand J, Polak M, Samara-Boustani D. Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring. European Journal Of Endocrinology 2023, 189: k19-k24. PMID: 37952170, DOI: 10.1093/ejendo/lvad147.Peer-Reviewed Original ResearchConceptsClassical congenital adrenal hyperplasiaClassical CAHCongenital adrenal hyperplasiaContinuous glucose monitoringLower cortisol concentrationsGlucose patternsAdrenal hyperplasiaCortisol concentrationsGlucose monitoringFludrocortisone replacement therapySensor glucose valuesHydrocortisone doseAcute illnessAsymptomatic hypoglycemiaWhole cohortNighttime hypoglycemiaReplacement therapyPercentage of timeObservational studyGlucose profilesGlycemic patternsSerial measuresGlucose valuesDaily cortisolHypoglycemiaObesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics
Santoro N, Galderisi A, Caprio S. Obesity, Growth, Development, Metabolic Disorder, and Insulin Resistance in Pediatrics. 2023, 608-616. DOI: 10.1201/9781003437673-70.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseType 2 diabetesInsulin resistanceAdolescent obesityCardiometabolic risk factorsMajor global health challengeFatty liver diseaseDevelopment of prediabetesGlobal health challengeClinical peculiaritiesFatty liverLiver diseasePediatric obesityRisk factorsPrecocious pubertyMetabolic disordersPathological complicationsObesityHealth challengesPsychosocial conditionsPotential mechanismsDiabetesEarly ageChildrenDyslipidemiaAlterations in Adipose Tissue Distribution, Cell Morphology, and Function Mark Primary Insulin Hypersecretion in Youth With Obesity
Tricò D, Chiriacò M, Nouws J, Vash-Margita A, Kursawe R, Tarabra E, Galderisi A, Natali A, Giannini C, Hellerstein M, Ferrannini E, Caprio S. Alterations in Adipose Tissue Distribution, Cell Morphology, and Function Mark Primary Insulin Hypersecretion in Youth With Obesity. Diabetes 2023, 73: 941-952. PMID: 37870826, PMCID: PMC11109779, DOI: 10.2337/db23-0450.Peer-Reviewed Original ResearchPrimary insulin hypersecretionΒ-cell glucose sensitivityAdipose tissue distributionInsulin hypersecretionInsulin resistanceGlucose toleranceUnfavorable metabolic phenotypeWorse glucose toleranceLeptin serum levelsAbnormal glucose toleranceTissue distributionExcessive insulin secretionHigher leptin levelsVisceral fat depotsNon-diabetic adolescentsEuglycemic hyperinsulinemic clampWhole-body adiposityAbdominal subcutaneous adipocytesBody weight gainGlucose sensitivityPrimary hypersecretionGlucose intoleranceSerum levelsLeptin levelsChronic hyperinsulinemiaNurturing the next generation of pediatric physician scientists: the Padova Physician Scientist Research Training for pediatric residents
Galderisi A, Bressan S, Da Dalt L, Perilongo G, Baraldi E. Nurturing the next generation of pediatric physician scientists: the Padova Physician Scientist Research Training for pediatric residents. European Journal Of Pediatrics 2023, 183: 1567-1570. PMID: 37851083, PMCID: PMC11001748, DOI: 10.1007/s00431-023-05258-9.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPediatric residentsEarly exposurePhysician scientistsResidency programsClinical trainingClinical trialsAnonymized questionnairePediatric programsPediatric residency programsPediatric trainingResearch trainingPediatric residencyPediatricsExposurePostgraduate medical educationMajor barrierResidencyFirst experienceResidentsMedical researchPhysiciansTrialsQuantifying beta cell function in the preclinical stages of type 1 diabetes
Galderisi A, Carr A, Martino M, Taylor P, Senior P, Dayan C. Quantifying beta cell function in the preclinical stages of type 1 diabetes. Diabetologia 2023, 66: 2189-2199. PMID: 37712956, PMCID: PMC10627950, DOI: 10.1007/s00125-023-06011-5.Peer-Reviewed Original ResearchConceptsType 1 diabetesBeta-cell functionInsulin secretionFunctional beta-cell massEarly pre-symptomatic stagesCell functionPre-symptomatic phaseBeta-cell massDisease-modifying interventionsPre-symptomatic stageContinuous glucose monitoringIslet autoimmunityInsulin sensitivityDisease progressionGlucose profilesInvasive measuresPreclinical stageMetabolic testsProgressive lossDiabetesMetabolic changesGlucose monitoringAvailable testsMeasurable changesOGTTSumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial
Golubic R, Ismail M, Josipovic M, Kennet J, Galderisi A, Evans M. Sumatriptan, a serotonin 5HT1B receptor agonist, acutely reduces insulin secretion and sensitivity and glucose effectiveness in overweight humans: A double‐blinded placebo‐controlled cross‐over trial. Diabetes Obesity And Metabolism 2023, 25: 3059-3063. PMID: 37312648, DOI: 10.1111/dom.15176.Peer-Reviewed Original ResearchConceptsPlacebo-controlled cross-over trialIntravenous glucose tolerance testGlucose tolerance testCross-over trialGlucose effectivenessTolerance testInsulin sensitivityInsulin secretionHyperinsulinaemic euglycaemic clampControl blood glucoseGlucoregulatory roleOverweight adultsOverweight humansEuglycaemic clampInsulin levelsGlucose excursionsBlood glucoseReceptor agonistMouse modelGlucose homeostasisSumatriptanPlaceboSecretionTrialsHumansP308 Strategies for the screening of glucose tolerance abnormalities and diabetes in people with cystic fibrosis: a French position statement
Weiss L, Reix P, Mosnier-Pudar H, Ronsin O, Beltrand J, Reynaud Q, Mely L, Burgel P, Stremler N, Rakotoarisoa L, Galderisi A, Perge K, Bendelac N, Abely M, Kessler L. P308 Strategies for the screening of glucose tolerance abnormalities and diabetes in people with cystic fibrosis: a French position statement. Journal Of Cystic Fibrosis 2023, 22: s158-s159. DOI: 10.1016/s1569-1993(23)00678-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNeurosteroid pathway derangement in asphyctic infants treated with hypothermia: an untargeted metabolomic approach
Valerio E, Stocchero M, Pirillo P, D’Errico I, Bonadies L, Galderisi A, Giordano G, Baraldi E. Neurosteroid pathway derangement in asphyctic infants treated with hypothermia: an untargeted metabolomic approach. EBioMedicine 2023, 92: 104636. PMID: 37257315, PMCID: PMC10244906, DOI: 10.1016/j.ebiom.2023.104636.Peer-Reviewed Original ResearchConceptsAsphyctic infantsHypoxic-ischemic encephalopathyHealthy newbornsPerinatal asphyxiaMetabolic effectsSingle-center longitudinal studyDays of lifeTherapeutic hypothermiaUrinary metabolomePathobiological mechanismsSteroid levelsInfantsHypothermiaSteroidogenesis pathwayUntargeted metabolomics approachNewbornsSteroid contentTranslational researchLongitudinal studyPotential roleAsphyxiaEncephalopathyMetabolomics approachPathway analysisUntargeted metabolomicsIn silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing
Libera A, Toffanin C, Drecogna M, Galderisi A, Pillonetto G, Cobelli C. In silico design and validation of a time-varying PID controller for an artificial pancreas with intraperitoneal insulin delivery and glucose sensing. APL Bioengineering 2023, 7: 026105. PMID: 37229215, PMCID: PMC10205143, DOI: 10.1063/5.0145446.Peer-Reviewed Original ResearchIP insulin deliveryInsulin deliveryPeritoneal spaceMeal announcementChronic autoimmune diseaseInsulin kineticsParadigm of treatmentBeta-cell functionIntraperitoneal insulin deliveryType 1 diabetesInpatient trialPeripheral hyperinsulinemiaMacrovascular complicationsGlycemic controlTwo-compartment modelInsulin replacementAutoimmune diseasesInsulin delivery systemsInsulin secretionDaily burdenInsulin pumpAid useCell functionArtificial pancreasDiseaseBeta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi A. Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us. Pediatric Endocrinology Diabetes And Metabolism 2023, 29: 1-3. PMID: 37218722, PMCID: PMC10226454, DOI: 10.5114/pedm.2023.126360.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBeta-cell functionType 1 diabetesIslet autoimmunityCell functionFunctional beta-cell massDisease-modifier drugsUnderlying autoimmune processPre-symptomatic phaseBeta-cell massSymptomatic diabetesAutoimmune processClinical onsetSurrogate markerDiabetes progressionC-peptideInsulin secretionModifier drugsEarly changesDiabetesMetabolic changesDysglycaemiaAutoimmunityT1DOnsetModifier treatmentScreening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis
Weiss L, Reix P, Mosnier-Pudar H, Ronsin O, Beltrand J, Reynaud Q, Mely L, Burgel P, Stremler N, Rakotoarisoa L, Galderisi A, Perge K, Bendelac N, Abely M, Kessler L. Screening strategies for glucose tolerance abnormalities and diabetes in people with cystic fibrosis. Diabetes & Metabolism 2023, 49: 101444. PMID: 37030530, DOI: 10.1016/j.diabet.2023.101444.Peer-Reviewed Original ResearchConceptsGlucose tolerance abnormalitiesCystic fibrosis-related diabetesTolerance abnormalitiesCystic fibrosisAnnual oral glucose tolerance testOral glucose tolerance testGlucose tolerance testLong asymptomatic periodStage of diabetesNew comorbiditiesAsymptomatic periodClinical profileTolerance testNew diagnostic toolsPathophysiological knowledgeDiabetesNutritional outcomesPatientsFibrosisAbnormalitiesScreening strategyLife expectancyDiagnostic toolScreening methodComorbidities